Ultragenyx (RARE) Jumped 7.5% on FDA Approval. Can a $2.7 Million Gene Therapy Become a Commercial Success?

Ultragenyx (RARE) Jumped 7.5% on FDA Approval. Can a $2.7 Million Gene Therapy Become a Commercial Success?

Tue, August 25, 2026 at 6:50 PM GMT+3 3 min read

• RARE +3.50%

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was up 7.5% in after-hours trading as of approximately 5:33 p.m. ET Wednesday after the FDA approved Genglycos for glycogen storage disease type Ia, or GSDIa. The one-time gene therapy is the first approved treatment designed to address the disorder's underlying cause. It will carry a U.S. list price of approximately $2.7 million per patient and is expected to become available through qualified treatment centers within 30 to 60 days.

The approval gives Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) first-mover status in a disease the company estimates affects only 1,500 to 2,500 Americans. The commercial question is whether a high-priced treatment for an ultra-rare population can produce meaningful revenue after diagnosis, reimbursement, and treatment-center constraints.

BULL CASE: A Meaningful Benefit Supports Premium Pricing

GSDIa prevents the liver from releasing glucose properly, leaving patients dependent on frequent raw-cornstarch doses to avoid potentially life-threatening hypoglycemia. In the Phase 3 GlucoGene trial, Genglycos reduced mean daily cornstarch intake by 41% at Week 48, compared with 10% for placebo, while maintaining glucose control. For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), reducing that daily burden creates a clear argument for premium pricing.

Longer-term data also support the treatment's potential durability. At Week 96, the original-treatment group reported a 61% mean reduction from baseline, while the crossover group reported a 61% reduction from Week 48, when it began treatment. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will manufacture the therapy at its Bedford, Massachusetts, facility, giving the company direct control over an important part of the supply chain.

The launch will also test infrastructure that could support future gene therapies. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) already sells rare-disease products including Crysvita, Dojolvi, Evkeeza and Mepsevii. Second-quarter revenue reached $214 million, while cash, cash equivalents, and marketable securities totaled $436 million as of June 30. Genglycos therefore enters a functioning commercial organization rather than a first-time launch platform.

BEAR CASE: The Addressable Market Is Exceptionally Small

The $2.7 million list price creates substantial potential gross revenue per patient before payer discounts, rebates, and access arrangements. However, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) must locate eligible patients, secure payer approval, and move them through qualified treatment centers. The total addressable population is already small, and annual demand could decline after the initial pool of identified patients receives a one-time therapy.

The approval also does not end the evidence burden. The FDA treated reduced cornstarch intake as a surrogate endpoint and requires additional clinical evidence to confirm effectiveness. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has agreed to provide two years of safety and efficacy data. Questions about durability matter particularly for a one-time treatment carrying a multimillion-dollar price.

INSIDER MONKEY'S HEDGE FUND DATA

Insider Monkey's hedge fund database shows that 55 hedge funds held positions in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) at the end of the first quarter, unchanged from the end of the preceding quarter. These figures reflect holdings as of March 31 and do not capture trades made after that date or investors' reactions to the Genglycos approval.

CONCLUSION

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has secured first-mover status, a premium price and evidence that Genglycos can reduce an exhausting daily treatment burden. The approval also strengthens its gene-therapy manufacturing and commercialization platform.

Still, the financial outcome depends on how many patients can be diagnosed, approved for reimbursement and treated each year. Genglycos can become a commercial success, but its value will be measured through launch execution rather than the headline list price.

While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: ConocoPhillips (COP): Wall Street Sees More Upside Despite Leadership Shakeup andHere is Why Chevron (CVX) is a Favorite Among Hedge Funds

Disclosure: None. This article is originally published at Insider Monkey.